In a move that underscores the growing momentum behind intratumoral cancer immunotherapies, GeoVax Labs, Inc. (Nasdaq: GOVX) has pointed to the recent U.S. Food and Drug Administration (FDA) accelerated approval of Replimune Group’s TUDRIQEV™ (formerly RP1) in combination with nivolumab as a key milestone. The approval, which covers adults with unresectable advanced cutaneous melanoma whose disease progressed after prior anti-PD-1 therapy, follows a favorable FDA Advisory Committee recommendation and marks a significant regulatory step for localized tumor-directed therapies used alongside immune checkpoint inhibitors (ICIs).
While TUDRIQEV and GeoVax’s investigational therapy Gedeptin® employ different mechanisms to kill tumor cells, GeoVax believes the approval reinforces a broader therapeutic paradigm: local destruction of tumor masses may modify the tumor microenvironment and potentially boost immune responses both at treated sites and at distant metastases.
“This approval represents an important milestone that extends well beyond any individual product,” said David A. Dodd, Chairman and CEO of GeoVax. “It provides clinical and regulatory precedent for locally administered therapies used in combination with checkpoint inhibition. We believe this represents an increasingly important direction for cancer immunotherapy.”
The concept of “priming” the tumor microenvironment is central to GeoVax’s strategy. Earlier this year, Dodd outlined this emerging idea in an Onco’Zine commentary titled The Cold Tumor Barrier: Why Promising Oncology Therapies Fail In Vivo – and What It Will Take to Overcome It. The article describes immunologically “cold” tumors—characterized by limited T-cell infiltration, poor antigen presentation, and an immunosuppressive microenvironment—as a fundamental barrier limiting the effectiveness of checkpoint inhibitors and other immunotherapies.
GeoVax posits that durable advances in immuno-oncology may depend on therapies that can convert these “cold” tumors into immune-responsive “hot” ones, thereby enabling checkpoint inhibitors to function more effectively. Gedeptin is designed to do this through a gene-directed enzyme prodrug therapy (GDEPT) approach. Unlike replication-dependent oncolytic viruses, Gedeptin uses a replication-deficient adenoviral vector to deliver the bacterial enzyme purine nucleoside phosphorylase (PNP) directly into tumor tissue. Subsequent administration of fludarabine phosphate leads to the conversion of the prodrug into a potent cytotoxic metabolite within the tumor, causing localized cell death and a bystander effect that extends beyond directly transduced cells, all while promoting anti-tumor immune responses.
Published research in JCI Insight demonstrated that Gedeptin combined with anti-PD-1 therapy in an immunocompetent preclinical model resulted in enhanced anti-tumor immune responses, increased CD8+ T-cell infiltration, systemic anti-tumor activity, and improved outcomes compared to checkpoint inhibition alone. These findings support the thesis that Gedeptin may act as a tumor-priming immunotherapy, helping to transform immunologically resistant tumors into those more responsive to checkpoint inhibition.
“The objective is not simply to destroy tumor cells locally,” said Kelly McKee, M.D., Chief Medical Officer of GeoVax. “The greater opportunity is to initiate the immune recognition necessary for checkpoint inhibitors to work more effectively. These findings demonstrate Gedeptin’s potential to combine extensive localized tumor killing with immune activation, creating a more favorable tumor microenvironment for checkpoint inhibition.”
The FDA approval of TUDRIQEV plus nivolumab establishes regulatory precedent for intratumoral/checkpoint inhibitor combinations, while the JCI Insight publication provides scientific evidence for Gedeptin’s synergy. GeoVax is preparing for the next phase of Gedeptin’s clinical development in combination with pembrolizumab for patients with head and neck squamous cell carcinoma, with plans to evaluate clinical activity and biomarkers of immune activation.
“The FDA approval of an intratumoral therapy combined with checkpoint inhibition reinforces a therapeutic direction that we believe has significant potential,” concluded Dodd. “Our objective with Gedeptin is to address one of the fundamental barriers limiting immunotherapy—the inability of immunologically cold tumors to generate an effective anti-tumor immune response.”
